Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze

Kathleen R. Bailey, Maria N. Pavlova, Alex D. Rohde, John G. Hohmann, Jacqueline Crawley

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

The neuropeptide galanin has been implicated in anxiety-related behaviors, cognition, analgesia, and feeding in rodents. Neuromodulatory actions of galanin are mediated by three G-protein coupled receptors, GalR1, GalR2, and GalR3. The present study investigates the role of the GalR2 receptor by evaluating behavioral phenotypes of mice with a targeted mutation in the GalR2 gene. A three-tiered behavioral phenotyping approach first examined control measures of general health, body weight, neurological reflexes, sensory abilities and motor function. Mice were then assessed on several tests for cognitive and anxiety-like behaviors. GalR2 null mutants and heterozygotes were not significantly different from wildtype littermates on two cognitive tests previously shown to be sensitive to galanin manipulation: acquisition of the Morris water maze spatial task, and trace cued and contextual fear conditioning, an emotional learning and memory task. Two independent cohorts of GalR2 null mutant mice demonstrated an anxiogenic-like phenotype in the elevated plus-maze. No genotype differences were detected on several other measures of anxiety-like behavior. The discovery of an anxiogenic phenotype specific to the elevated plus-maze, similar to findings in GalR1 null mutants, highlights the potential therapeutic efficacy of targeting GalR1 and GalR2 receptors in treating anxiety disorders.

Original languageEnglish (US)
Pages (from-to)8-20
Number of pages13
JournalPharmacology Biochemistry and Behavior
Volume86
Issue number1
DOIs
StatePublished - Jan 2007
Externally publishedYes

Fingerprint

Receptor, Galanin, Type 2
Galanin Receptors
Phenotype
Galanin
Anxiety
Aptitude
Heterozygote
G-Protein-Coupled Receptors
Anxiety Disorders
Neuropeptides
Analgesia
Cognition
Fear
Reflex
Rodentia
Genes
Genotype
Body Weight
Health
Learning

Keywords

  • Anxiogenic-like
  • Galanin
  • GalR2 null mutant
  • Learning
  • Memory
  • Mice
  • Neuropeptide
  • Nociception

ASJC Scopus subject areas

  • Biochemistry
  • Behavioral Neuroscience
  • Pharmacology

Cite this

Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze. / Bailey, Kathleen R.; Pavlova, Maria N.; Rohde, Alex D.; Hohmann, John G.; Crawley, Jacqueline.

In: Pharmacology Biochemistry and Behavior, Vol. 86, No. 1, 01.2007, p. 8-20.

Research output: Contribution to journalArticle

@article{555a1c6032fa48479727a555a8551115,
title = "Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze",
abstract = "The neuropeptide galanin has been implicated in anxiety-related behaviors, cognition, analgesia, and feeding in rodents. Neuromodulatory actions of galanin are mediated by three G-protein coupled receptors, GalR1, GalR2, and GalR3. The present study investigates the role of the GalR2 receptor by evaluating behavioral phenotypes of mice with a targeted mutation in the GalR2 gene. A three-tiered behavioral phenotyping approach first examined control measures of general health, body weight, neurological reflexes, sensory abilities and motor function. Mice were then assessed on several tests for cognitive and anxiety-like behaviors. GalR2 null mutants and heterozygotes were not significantly different from wildtype littermates on two cognitive tests previously shown to be sensitive to galanin manipulation: acquisition of the Morris water maze spatial task, and trace cued and contextual fear conditioning, an emotional learning and memory task. Two independent cohorts of GalR2 null mutant mice demonstrated an anxiogenic-like phenotype in the elevated plus-maze. No genotype differences were detected on several other measures of anxiety-like behavior. The discovery of an anxiogenic phenotype specific to the elevated plus-maze, similar to findings in GalR1 null mutants, highlights the potential therapeutic efficacy of targeting GalR1 and GalR2 receptors in treating anxiety disorders.",
keywords = "Anxiogenic-like, Galanin, GalR2 null mutant, Learning, Memory, Mice, Neuropeptide, Nociception",
author = "Bailey, {Kathleen R.} and Pavlova, {Maria N.} and Rohde, {Alex D.} and Hohmann, {John G.} and Jacqueline Crawley",
year = "2007",
month = "1",
doi = "10.1016/j.pbb.2006.11.024",
language = "English (US)",
volume = "86",
pages = "8--20",
journal = "Pharmacology Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze

AU - Bailey, Kathleen R.

AU - Pavlova, Maria N.

AU - Rohde, Alex D.

AU - Hohmann, John G.

AU - Crawley, Jacqueline

PY - 2007/1

Y1 - 2007/1

N2 - The neuropeptide galanin has been implicated in anxiety-related behaviors, cognition, analgesia, and feeding in rodents. Neuromodulatory actions of galanin are mediated by three G-protein coupled receptors, GalR1, GalR2, and GalR3. The present study investigates the role of the GalR2 receptor by evaluating behavioral phenotypes of mice with a targeted mutation in the GalR2 gene. A three-tiered behavioral phenotyping approach first examined control measures of general health, body weight, neurological reflexes, sensory abilities and motor function. Mice were then assessed on several tests for cognitive and anxiety-like behaviors. GalR2 null mutants and heterozygotes were not significantly different from wildtype littermates on two cognitive tests previously shown to be sensitive to galanin manipulation: acquisition of the Morris water maze spatial task, and trace cued and contextual fear conditioning, an emotional learning and memory task. Two independent cohorts of GalR2 null mutant mice demonstrated an anxiogenic-like phenotype in the elevated plus-maze. No genotype differences were detected on several other measures of anxiety-like behavior. The discovery of an anxiogenic phenotype specific to the elevated plus-maze, similar to findings in GalR1 null mutants, highlights the potential therapeutic efficacy of targeting GalR1 and GalR2 receptors in treating anxiety disorders.

AB - The neuropeptide galanin has been implicated in anxiety-related behaviors, cognition, analgesia, and feeding in rodents. Neuromodulatory actions of galanin are mediated by three G-protein coupled receptors, GalR1, GalR2, and GalR3. The present study investigates the role of the GalR2 receptor by evaluating behavioral phenotypes of mice with a targeted mutation in the GalR2 gene. A three-tiered behavioral phenotyping approach first examined control measures of general health, body weight, neurological reflexes, sensory abilities and motor function. Mice were then assessed on several tests for cognitive and anxiety-like behaviors. GalR2 null mutants and heterozygotes were not significantly different from wildtype littermates on two cognitive tests previously shown to be sensitive to galanin manipulation: acquisition of the Morris water maze spatial task, and trace cued and contextual fear conditioning, an emotional learning and memory task. Two independent cohorts of GalR2 null mutant mice demonstrated an anxiogenic-like phenotype in the elevated plus-maze. No genotype differences were detected on several other measures of anxiety-like behavior. The discovery of an anxiogenic phenotype specific to the elevated plus-maze, similar to findings in GalR1 null mutants, highlights the potential therapeutic efficacy of targeting GalR1 and GalR2 receptors in treating anxiety disorders.

KW - Anxiogenic-like

KW - Galanin

KW - GalR2 null mutant

KW - Learning

KW - Memory

KW - Mice

KW - Neuropeptide

KW - Nociception

UR - http://www.scopus.com/inward/record.url?scp=33847223866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847223866&partnerID=8YFLogxK

U2 - 10.1016/j.pbb.2006.11.024

DO - 10.1016/j.pbb.2006.11.024

M3 - Article

C2 - 17257664

AN - SCOPUS:33847223866

VL - 86

SP - 8

EP - 20

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

SN - 0091-3057

IS - 1

ER -